CO2024000205A2 - Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones - Google Patents
Arn adsorbido en partículas de nanoemulsión lipídica y sus formulacionesInfo
- Publication number
- CO2024000205A2 CO2024000205A2 CONC2024/0000205A CO2024000205A CO2024000205A2 CO 2024000205 A2 CO2024000205 A2 CO 2024000205A2 CO 2024000205 A CO2024000205 A CO 2024000205A CO 2024000205 A2 CO2024000205 A2 CO 2024000205A2
- Authority
- CO
- Colombia
- Prior art keywords
- formulations
- nanoemulsion particles
- rna
- lipid nanoemulsion
- adsorbed
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 239000007908 nanoemulsion Substances 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 239000002539 nanocarrier Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121031414A IN202121031414A (enExample) | 2021-07-13 | 2021-07-13 | |
| PCT/IN2022/050624 WO2023286076A1 (en) | 2021-07-13 | 2022-07-08 | Rna adsorbed onto lipid nano-emulsion particles and its formulations. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000205A2 true CO2024000205A2 (es) | 2024-01-25 |
Family
ID=84920187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000205A CO2024000205A2 (es) | 2021-07-13 | 2024-01-12 | Arn adsorbido en partículas de nanoemulsión lipídica y sus formulaciones |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240325522A1 (enExample) |
| EP (1) | EP4351521A4 (enExample) |
| JP (1) | JP2024525709A (enExample) |
| KR (1) | KR20240035836A (enExample) |
| AU (1) | AU2022310435A1 (enExample) |
| CA (1) | CA3226213A1 (enExample) |
| CL (1) | CL2024000120A1 (enExample) |
| CO (1) | CO2024000205A2 (enExample) |
| IN (1) | IN202121031414A (enExample) |
| WO (1) | WO2023286076A1 (enExample) |
| ZA (1) | ZA202400149B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
| CA3232658A1 (en) | 2021-09-22 | 2023-03-30 | Steven Gregory REED | Rna vaccines against infectious diseases |
| AU2022352486A1 (en) | 2021-09-22 | 2024-04-11 | Hdt Bio Corp. | Dried nanoparticle compositions |
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| JP2024535352A (ja) | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Ｓａｒｓ－ｃｏｖ－２ ｒｎａワクチン組成物および使用方法 |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2023094713A2 (en) * | 2021-11-29 | 2023-06-01 | BioNTech SE | Coronavirus vaccine |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024261766A1 (en) * | 2023-06-23 | 2024-12-26 | Gennova Biopharmaceuticals Ltd. | Lyophilised vaccine formulation |
| EP4734962A1 (en) * | 2023-06-29 | 2026-05-06 | RIGImmune Inc. | Novel formulations |
| WO2026093528A1 (en) * | 2024-10-31 | 2026-05-07 | Etherna Immunotherapies Nv | A purification of rna by flowthrough chromatography |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9636410B2 (en) * | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| AU2018285694B2 (en) * | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
-
2021
- 2021-07-13 IN IN202121031414A patent/IN202121031414A/en unknown
-
2022
- 2022-07-08 AU AU2022310435A patent/AU2022310435A1/en active Pending
- 2022-07-08 US US18/578,881 patent/US20240325522A1/en active Pending
- 2022-07-08 WO PCT/IN2022/050624 patent/WO2023286076A1/en not_active Ceased
- 2022-07-08 CA CA3226213A patent/CA3226213A1/en active Pending
- 2022-07-08 EP EP22841629.3A patent/EP4351521A4/en active Pending
- 2022-07-08 KR KR1020247004893A patent/KR20240035836A/ko active Pending
- 2022-07-08 JP JP2024501633A patent/JP2024525709A/ja active Pending
-
2024
- 2024-01-03 ZA ZA2024/00149A patent/ZA202400149B/en unknown
- 2024-01-12 CO CONC2024/0000205A patent/CO2024000205A2/es unknown
- 2024-01-15 CL CL2024000120A patent/CL2024000120A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN202121031414A (enExample) | 2023-01-13 |
| EP4351521A4 (en) | 2025-12-10 |
| CL2024000120A1 (es) | 2024-08-16 |
| ZA202400149B (en) | 2024-08-28 |
| AU2022310435A1 (en) | 2024-01-25 |
| KR20240035836A (ko) | 2024-03-18 |
| US20240325522A1 (en) | 2024-10-03 |
| EP4351521A1 (en) | 2024-04-17 |
| CA3226213A1 (en) | 2023-01-19 |
| JP2024525709A (ja) | 2024-07-12 |
| WO2023286076A1 (en) | 2023-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2024000120A1 (es) | Arn adorbido sobre partículas de nanoemulsión lipídica y sus formulaciones. | |
| MX2019004913A (es) | Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm). | |
| MX2019005287A (es) | Lipidos cationicos para suministro de acido nucleico y su preparacion. | |
| SI3368507T1 (sl) | Novi lipidi in formulacije lipidnih nanodelcev za dostavo nukleinskih kislin | |
| AR113782A1 (es) | Preparación y almacenamiento de formulaciones de arn liposomal adecuadas para tratamiento | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| CO2021005774A2 (es) | Lípidos con amina ionizables | |
| MX2023005696A (es) | Composiciones de lnp que comprenden arn y metodos para preparar, almacenar y usar las mismas. | |
| MX2023008328A (es) | Nanomateriales que comprenden una caracteristica biodegradable. | |
| CO2019007258A2 (es) | Arn guía modificados | |
| CL2025001086A1 (es) | Molécula de unión a antígeno anti cd137 y sus usos | |
| MX2019005470A (es) | Formulación de nanopartículas lipídicas basadas en ice mejorada para el suministro de arnm. | |
| MX2017017079A (es) | Sistema de administracion dirigida de principio activo celular. | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| MX377244B (es) | Formulacion arn para inmunoterapia. | |
| CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
| MX2022006512A (es) | Lipidos cationicos de trialquilo y metodos de uso de los mismos. | |
| GT201500330A (es) | Composiciones y métodos de uso de interferencia de arn en serpina 1 | |
| GT201400164A (es) | Compuestos de imidazopirrolidinona | |
| MX2025004779A (es) | Formulaciones de proteinas de fusion vegfr-fc | |
| TR201816986T4 (tr) | Terapötik ajan iletim formülasyonlarına yönelik lipitler. | |
| WO2013177421A3 (en) | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same | |
| PE20181131A1 (es) | COMPOSICIONES DE ARNi PARA LIGANDO 1 DE MUERTE CELULAR PROGRAMADA 1 (PD-L1) Y METODOS DE USO DE LAS MISMAS | |
| AU2015329974A8 (en) | GaINAc phosphoramidites, nucleic acid conjugates thereof and their use | |
| BR112018012262A2 (pt) | composições de interleucina-15 e seus usos |